A practical reference on GLP-1 receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-09 and is reviewed periodically as new material appears.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
On 27 July, an Israeli strike in southern Lebanon killed four members of different militant groups. A rocket strike hit the Druze town of Majdal Shams in the northern Golan Heights, killing 12 children and injuring dozens more. In retaliation, the IDF bombed villages and towns in south and east Lebanon the following day. On 29 July, two were killed in an Israeli strike in Lebanon. The next day, an Israeli airstrike struck Hezbollah infrastructure in southern Lebanon, and one Israeli civilian was killed in a rocket strike from Lebanon to northern Israel. Hezbollah said it fired at Israeli warplanes which entered Lebanese airspace. The IDF said the airstrike targeted senior commander of Hezbollah Fuad Shukr for his involvement in the Majdal Shams attack, and Hezbollah later confirmed his death. Four civilians were also killed, while 80 people were injured. On 17 August, at least 11 including a woman and her two children were killed and four were wounded including two serious injuries in an Israeli strike on a metal warehouse in Nabatieh. The IDF claimed that it struck a Hezbollah "weapons storage facility". The Embassy of the Philippines, Beirut advised its 11,000 citizens in Lebanon to leave the country following the strike. A Hezbollah drone strike injured two soldiers in an IDF site near Misgav Am. One was killed in an Israeli drone strike on a motorcycle in Tyre. The IDF confirmed the death of a commander of the elite Redwan Force.
The use of different fuels in nuclear reactors results in different spent nuclear fuel (SNF) composition, with varying activity curves. The most abundant material being U-238 with other uranium isotopes, other actinides, fission products and activation products. Long-lived radioactive waste from the back end of the fuel cycle is especially relevant when designing a complete waste management plan for SNF. When looking at long-term radioactive decay, the actinides in the SNF have a significant influence due to their characteristically long half-lives. Depending on what a nuclear reactor is fueled with, the actinide composition in the SNF will be different. An example of this effect is the use of nuclear fuels with thorium. Th-232 is a fertile material that can undergo a neutron capture reaction and two beta minus decays, resulting in the production of fissile U-233. The SNF of a cycle with thorium will contain U-233. Its radioactive decay will strongly influence the long-term activity curve of the SNF for around a million years. A comparison of the activity associated to U-233 for three different SNF types can be seen in the figure on the top right. The burnt fuels are thorium with reactor-grade plutonium (RGPu), thorium with weapons-grade plutonium (WGPu), and Mixed oxide fuel (MOX, no thorium). For RGPu and WGPu, the initial amount of U-233 and its decay for around a million years can be seen. This has an effect on the total activity curve of the three fuel types.
== Names == Dapagliflozin is the international nonproprietary name (INN), and the United States Adopted Name (USAN). The fixed-dose combination product, dapagliflozin/metformin extended-release, is sold under the brand name Xigduo XR. In July 2016, the fixed-dose combination of saxagliptin and dapagliflozin was authorized for medical use in the European Union and is sold under the brand name Qtern. The combination drug was approved for medical use in the United States in February 2017, where it also is sold under the brand name Qtern. In May 2019, the fixed-dose combination of dapagliflozin, saxagliptin, and metformin hydrochloride as extended-release tablets was approved in the United States to improve glycemic control in adults with type 2 diabetes when used in combination with diet and exercise. The FDA granted the approval of Qternmet XR to AstraZeneca. The combination drug was authorized for use in the European Union in November 2019, and is sold under the brand name Qtrilmet.
The starting material was an N-substituted pyrrole derivative, which was heated to convert it by a [1,5] sigmatropic shift to the isomer with a carbon bond between the pyrrole and pyridine rings, followed by methylation and selective reduction of the pyrrole ring using tin and hydrochloric acid. Many other syntheses of nicotine, in both racemic and chiral forms have since been published.
Sources: en.wikipedia.org
The idea that life originated from non-living matter in slow stages appeared in Herbert Spencer's 1864–1867 book Principles of Biology, and in William Turner Thiselton-Dyer's 1879 paper "On spontaneous generation and evolution". On 1 February 1871 Charles Darwin wrote about these publications to Joseph Hooker, and set out his own speculation that the original spark of life may have been in a "warm little pond, with all sorts of ammonia and phosphoric salts,—light, heat, electricity &c present, that a protein compound was chemically formed". Darwin explained that "at the present day such matter would be instantly devoured or absorbed, which would not have been the case before living creatures were formed." Alexander Oparin in 1924 and J. B. S. Haldane in 1929 proposed that the earliest cells slowly self-organized from a primordial soup, the Oparin–Haldane hypothesis. Haldane suggested that the Earth's prebiotic oceans consisted of a "hot dilute soup" in which organic compounds could have formed. J. D. Bernal showed that such mechanisms could form most of the necessary molecules for life from inorganic precursors. In 1967, he suggested three "stages": the origin of biological monomers; the origin of biological polymers; and the evolution from molecules to cells.
Elastin is a protein encoded by the ELN gene in humans and several other animals. Elastin is a key component in the extracellular matrix of gnathostomes (jawed vertebrates). It is highly elastic and present in connective tissue of the body to resume its shape after stretching or contracting. Elastin helps skin return to its original position when poked or pinched. Elastin is also in important load-bearing tissue of vertebrates and used in places where storage of mechanical energy is required.
In the 12th century BCE, many Israelite settlements appeared in the central hill country of Canaan, which was formerly an open terrain. These settlements lacked evidence of pork consumption, compared to Philistine settlements, had four-room houses and lived by an egalitarian ethos, which was exemplified by the absence of elaborate tombs, governor's mansions, certain houses being bigger than others etc. They followed a mixed economy, which prioritized self-sufficiency, cultivation of crops, animal husbandry and small-scale craft production. New technologies such as terraced farming, silos for grain storage and cisterns for rainwater collection were simultaneously introduced. These settlements were built by inhabitants of the "general Southland" (i.e. modern Sinai and the southern parts of Israel and Jordan), who abandoned their pastoral-nomadic ways. Canaanites who lived outside the central hill country were tenuously identified as Danites, Asherites, Zebulunites, Issacharites, Naphtalites and Gadites. These inhabitants do not have a significant history of migration besides the Danites, who allegedly originate from the Sea Peoples, particularly the Dan(an)u. Nonetheless, they intermingled with the former nomads, due to socioeconomic and military factors. Their interest in Yahwism and its concern for the underprivileged was another factor. Possible allusions to this historical reality in the Hebrew Bible include the aforementioned tribes, except for Issachar and Zebulun, descending from Bilhah and Zilpah, who were viewed as "secondary additions" to Israel.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
差别集中在三处：第 8 位残基被非天然氨基酸取代，第 34 位换成精氨酸，第 26 位增加一条脂肪酸侧链。前两处改动降低酶解速率，侧链则通过白蛋白结合延长循环时间。综合结果是半衰期从约两分钟延长到约一周。